Dual monoclonal antibody immunoassay for free prostate-specific antigen

Prostate

Volumn 28, Issue 1, 1996, Pages 10-16

  Wang, Tang J ^a   Hill, Tim M ^a   Sokoloff, Roger L ^a   Frankenne, Francis ^b   Rittenhouse, Harry G ^a   Wolfert, Robert L ^a  

^a Hybritech Incorporated   (United States)

^b Hybritech SA   (Belgium)

Author keywords

BPH; free PSA; immunoassay; prostate cancer

Indexed keywords

MONOCLONAL ANTIBODY; PROSTATE SPECIFIC ANTIGEN;

ARTICLE; CONTROLLED STUDY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; HUMAN; HUMAN TISSUE; IMMUNOASSAY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; SERUM;

ADULT; ANTIBODIES, MONOCLONAL; EPITOPE MAPPING; EPITOPES; FEMALE; HUMANS; IMMUNOASSAY; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; ROC CURVE; SENSITIVITY AND SPECIFICITY;

EID: 0030068667     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0045(199601)28:1<10::AID-PROS2>3.0.CO;2-S     Document Type: Article

References (26)

1. Wang MC, Papsidero LD, Kuriyama M, Valenzuela LA, Murphy GP, Chu TM: Prostate antigen: A new potential marker for prostatic cancer. Prostate 2:89-96, 1981.
2. Loor R, Watt KWK: Molecular and biological characteristics of prostate-specific antigen. Catalona WJ, Coffey D, Karr JP (eds): "Clinical Aspects of Prostate Cancer." New York: Elsevier Science, 1989.
3. Lundwall A, Lilja H: Molecular cloning of human prostate specific antigen cDNA. FEBS Lett 214:317-322, 1987.
4. McCormack RT, Rittenhouse HG, Finlay JA, Sokoloff RL, Wang TJ, Wolfert RL, Lilja H, Oesterling JE: Molecular forms of prostate-specific antigen (PSA) and the human kallikrein family: A new era. Urology 45:729-744, 1995.
5. Lilja H: A kallikrein-like serine protease in prostatic fluid cleaves the predominant seminal vesicle protein. J Clin Invest 76:1899-1903, 1985.
6. Kanety H, Madjar Y, Dagan Y, Levi J, Papa MZ, Pariente C, Goldwasser B, Karasik A: Serum insulin-like growth factor-binding protein-2 (IGFBP-2) is increased and IGFBP-3 is decreased in patients with prostate cancer: Correlation with serum prostate-specific antigen. J Clin Endocrin Metab 77:229-233, 1992.
7. Oesterling JE: Prostate specific antigen: A critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol 145:907-923, 1991.
8. Catalona WJ, Richie JP, Ahmann FR, Hudson MA, Scardino PT, Flanigan RC, deKernion JB, Ratliff TL, Kavoussi LR, Dalkin BL, et al: Comparison of digital rectal examination and serum prostate specific antigen (PSA) in the early detection of prostate cancer: Results of a multicenter clinical trial of 6,630 men. J Urol 151: 1283-1290, 1994.
9. Hudson MA, Bahnson RR, Catalona WJ: Clinical use of prostate specific antigen in patients with prostate cancer. J Urol 142:1011-1017, 1989.
10. Takayama TK, Vessella RL, Brawer MK, True LD, Noteboom J, Lange PH: Urinary prostate-specific antigen levels after radical prostatectomy. J Urol 151:82-87, 1994.
11. Kavadi VS, Zagars GK, Pollack A: Serum prostate-specific antigen after radiation-therapy for clinically localized prostate-cancer-prognostic implications. Int J Radiat Oncol Biol Phys 30:279-287, 1994.
12. Christensson A, Laurell C-B, Lilja H: Enzymatic activity of prostate-specific antigen and its reactions with extracellular serine proteinase inhibitors. Eur J Biochem 194: 755-763, 1990.
13. Stenman U-H, Leinonen J, Alfthan H, Rannikko S, Tuhkanen K, Alfthan O: A complex between prostate-specific antigen and α-1 antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: Assay of the complex improves clinical sensitivity for cancer. Cancer Res 51:222-226, 1991.
14. Christensson A, Bjork T, Nilsson O, Dahlen U, Matikainen M-T, Cockett ATK, Abrahamsson P-A, Lilja H: Serum prostate specific antigen complexed to α-1 antichymotrypsin as an indicator of prostate cancer. J Urol 150:100-105, 1993.
15. Wang TJ, Rittenhouse HG, Wolfert RL: Characterization of five different epitopes of Anti-PSA monoclonal antibodies. Clin Chem 41:s229, 1995.
16. Sensabaugh GF, Blake ET: Seminal plasma protein p30: Simplified purification and evidence for identity with prostate specific antigen. J Urol 144:1523-1526, 1990.
17. Hemmila I, Dakubu S, Mukkala V-M, Siitari H, Lovgren T: Europium as a label in time-resolved immunofluorometric assays. Anal Biochem 137:335-343, 1984.
18. Zweig MH, Campbell G: Receiver-operating characteristic (ROC) plots: A fundamental evaluation tool in clinical medicine. Clin Chem 39:561-577, 1993.
19. Oesterling JE, PSA leads the way for detecting and following prostate cancer. Contemp Urol 5(2):60-82, 1993.
20. Sershon PD, Barry MJ, Oesterling JE: Serum prostate-specific antigen discriminates weakly between men with benign prostatic hyperplasia and patients with organ-confined prostate cancer. Eur Urol 25:281-287, 1994.
21. Partin AW, Carter HB, Chan DW, Epstein JI, Oesterling JE, Rock RC, Weber JP, Walsh PC: Prostate specific antigen in the staging of localized prostate cancer: Influence of tumor differentiation, tumor volume and benign hyperplasia. J Urol 143:747-752, 1990.
22. Richie JP, Catalona WJ, Ahmann FR, Hudson MA, Scardino PT, Flanigan RC, deKernion JB, Ratliff TL, Kavoussi LR, Dalkin BL, et al: Effect of patient age on early detection of prostate cancer with serum prostate-specific antigen and digital rectal examination. Urol 42: 365-374, 1993.
23. Sokoloff RL, Esgate JA, Wang TJ, Strobel SA, Rittenhouse HG: Effect of prostate-specific antigen forms on PSA quantitation. J Urol 151:450A, 1994.
24. Strobel SA, Sokoloff RL, Wolfert RL, Rittenhouse HG: Multiple forms of prostate-specific antigen in serum measured differently in equimolar- and skewed-response assays. Clin Chem 41:125, 1995.
25. Graves H: Issues on standardization of immunoassays for prostate specific antigen: A review. Clin Invest Med 16:415-424, 1993.
26. Sokoloff RL, Wolfert RL, Rittenhouse HG: Standardization of PSA immunoassays: Proposals and practical limitations. Journal of Clinical Ligand Assay 18:86-92, 1995.